Contents:
Our goal is to bring this to phase one trials soon.
Our program's extraordinary basic and translational scientists are working in a partnership to better understand the underlying biology of prostate cancer and to improve treatment options. Researchers at Duke and elsewhere have found that African American men are two times more likely to be diagnosed with prostate cancer than white men and three times more likely to die from prostate cancer than white men.
Much of this disparity remains even after controlling for factors related to access to care. In fact, we have identified novel biological differences that drive a more aggressive prostate cancer in African American men. Ultimately, through our research, we hope to reduce the disproportionate burden of prostate cancer on African Americans and improve clinical outcomes for men of all races with aggressive prostate cancer.
Bryan Senter , Administrative Director Phone: To make an appointment, please call For more information on genitourinary cancer care at Duke Health, visit:. They say it's really the journey that teaches us a lot about our destination. Dominic Marrese could have never anticipated 10 years ago when he was diagnosed with prostate cancer that today he would be an outspoken advocate for prostate cancer screening and a committed champion for increased funding to move science forward.
Become a member and get access to the benefits: Ultimately, through our research, we hope to reduce the disproportionate burden of prostate cancer on African Americans and improve clinical outcomes for men of all races with aggressive prostate cancer. Dominic Marrese could have never anticipated 10 years ago when he was diagnosed with prostate cancer that today he would be an outspoken advocate for prostate cancer screening and a committed champion for increased funding to move science forward. For more information on genitourinary cancer care at Duke Health, visit:. In bladder and prostate cancer, this ratio drops to one suicide for every 7 attempts. For almost 40 years the EAU has addressed the most pressing issues of urological care in Europe, through its scientific and educational initiatives, as well as its publications. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.
We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war. Research Focus Areas Metastasis Biology and Precision Medicine Metastasis, the spread of cancer beyond the site of origin, accounts for the majority of lethal cancers in the U.
Immunotherapies for Aggressive Prostate Cancer Prostate cancer was one of the first cancers to positively respond to immunotherapy treatment; specifically to the drug sipuleucel-T Provenge. Members have advanced access to the Resource Centre. For any successful clinician, having the most up-to-date evidence-based recommendations on hand is crucial for the successful treatment of your patients.
The EAU Guidelines are unparalleled in that regard, used all across the world. They are comprehensively updated on an annual basis and freely accessible for all members.
Urologists are bound by national and, increasingly, international laws that govern treatment options and patient care. The EAU brings together the voices of medical professionals, researchers, innovators and patients on a European platform to keep urological topics on the agendas of the authorities. The EAU offers a wide range of events and courses to interact with the best specialists in the field of urology. The Annual EAU Congress is the largest urology-related event in the world where you can network with like-minded professionals.
It is one of the most widely-cited medical journals in the world and, with an impact factor of Additionally, the independent EAU Research Foundation conducts clinical trials to add valuable data to the pool of scientific knowledge in Europe. Only as a member you are eligible to apply for grants and funding.
For almost 40 years the EAU has addressed the most pressing issues of urological care in Europe, through its scientific and educational initiatives, as well as its publications. Become a member and get access to the benefits:.
9th European Multidisciplinary Meeting on Urological Cancers where critical insights on current and prospective treatment strategies will be discussed platform for scientific discussions that address emerging trends in urological cancers. There are many types of urological cancer. Some types can be Learn more about our cancer care at Beaumont. Urological Cancer Multidisciplinary Clinic.
Urology Week is an initiative of the European Association of Urology, which brings together national urological societies, urology practitioners, urology nurses, the patients and their families, and politicians to create awareness of urological conditions among the general public. During Urology Week, our goal is to raise awareness of what urology is truly about.
Kasivisvanathan brings us to up to date with a major study demonstrating that prostate MRI reveals more cancers, compared to standard biopsy. Dr Martha Haahr and Prof. Jens Sonksen talk about anew clinical trial showing that stem cells can restore sufficient erectile function to allow previously impotent men to have spontaneous intercourse.
More than half a million prostatecancer patients could be affected if Brexit negotiations fail, the Brexit Health… https: The state of urological cancers in Europe: In the meantime in Prague, the esunmibc18 course of urowebESU is taking place https: Thousands of cases to be reviewed https: